MedTrace Logo

Medium Chain Triglycerides (MCT) and Whey Protein Isolate (WPI) for Type 2 Diabetes Patients (Combine)

NCT04905589 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2024-10-22

No results posted yet for this study

Summary

Evaluation of effect on diurnal glycaemia following consumption of MCT and whey protein in patients with type 2 diabetes

Conditions

Interventions

DIETARY_SUPPLEMENT

BetaQuik™

MCT (Medium chain triglycerides)

DIETARY_SUPPLEMENT

WheyBasics

Whey Protein Isolate

OTHER

Iso-voluminous water

Iso-voluminous Water as comparitor to Betaquik or WheyBasics

Sponsors & Collaborators

  • Société des Produits Nestlé (SPN)

    lead INDUSTRY

Principal Investigators

  • Professor Kostas Tsintzas · University of Nottingham

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
25 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-30
Primary Completion
2022-08-01
Completion
2022-08-01

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04905589 on ClinicalTrials.gov